Transdermal Drug Delivery Systems Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Transdermal Drug Delivery Systems Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • November 2021 •
  • 143 pages •
  • Report ID: 6185732 •
  • Format: PDF
The global transdermal drug delivery systems market exhibited moderate growth during 2015-2020.

Looking forward, the analyst expects the market to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.

The transdermal drug delivery system (TDDS) is an alternative system of delivering drugs through the skin for systemic distribution. It is used as an alternative to oral intravascular, subcutaneous, and transmucosal routes. TDDS supports both chronic and acute diseases as well as cosmetic procedures as it delivers biologically active agents, such as drugs and cosmeceuticals, through the skin. It offers a controlled release of drugs, which reduces the first-pass metabolism effects, lessens the side effects, and improves the efficacy of the dosage by enabling a steady blood drug profile throughout the treatment.

Transdermal Drug Delivery System Market Trends:
The global transdermal drug delivery systems market is primarily driven by the growing instances of chronic disorders that cannot be treated through conventional drug delivery systems, such as oral drugs. Patients with long-term ailments, such as diabetes, are shifting toward self-administration of medicine. As a result, there has been an introduction of adhesive skin patches to administer the daily course of medication without the pain. This has encouraged patients and physicians to prefer pain-free drug delivery systems. Besides this, the wide adoption of third-generation transdermal drug delivery systems like iontophoresis promotes self-reliance in patients since it reduces frequent visits to hospitals and lessens the cumulative treatment costs. Furthermore, technological advancements, such as the inclusion of microneedles, modifications in transdermal patch designs and the incorporation of pressure-sensitive adhesives and permeation enhancers, are providing vast opportunities to manufacturers.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global transdermal drug delivery systems market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, technology and application.

Breakup by Technology:
Electroporation
Radiofrequency
Iontophoresis
Microporation
Thermal
Mechanical Arrays
Ultrasound
Others

Breakup by Application:
Central Nervous System
Pain Management
Cardiovascular
Hormone
Others

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Acrux Limited, Boehringer Ingelheim International GmbH, Hisamitsu Pharmaceutical Co. Inc., Lavipharm S.A., LEAD CHEMICAL Co. Ltd., Luye Pharma Group, Nutriband Inc. and Viatris Inc. Key Questions Answered in This Report:
How has the global transdermal drug delivery systems market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global transdermal drug delivery systems market?
What are the key regional markets?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global transdermal drug delivery systems market and who are the key players?
What is the degree of competition in the industry?